bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
Forecasting between $9.2 and $9.6 million in 2024 revenues for wholly owned subsidiary Precision Pathology Laboratory Services (PPLS), up 23% over 2023.
- Forecasting between $9.2 and $9.6 million in 2024 revenues for wholly owned subsidiary Precision Pathology Laboratory Services (PPLS), up 23% over 2023.
- Increased 2024 CyPath® Lung sales forecast 35% from the original forecast reported in the 2023 Annual Report.
- Number of physician offices ordering CyPath® Lung is up 112%, more than double, since January 1, 2024.
- Physicians in Pennsylvania, New Jersey, North Carolina, Arizona, and Michigan are ordering CyPath® Lung after hearing about it from patients and colleagues.